AmpliPhi Biosciencess C3J Logo

Armata has joined together two seasoned drug development teams, AmpliPhi Biosciences and C3J Therapeutics, to tackle the global and increasingly serious threat of antimicrobial-resistant bacterial infections. Driven by rigorous and innovative science, Armata is developing high-impact, best-in-class bacteriophage therapeutics with the potential to save millions of lives.

Armata Pharmaceuticals
Enter

Pipeline Overview

Armata’s therapeutic phage candidates aim to address areas of significant unmet clinical need, by targeting key antibiotic-resistant bacteria including those on the World Health Organization’s global priority pathogens list. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent are being developed in partnership with Merck. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing.

divider
Pathogen / Indication Discovery Preclinical IND-Enabling CMC Phase 1b/2
Pseudomonas aeruginosa
Cystic Fibrosis Lung Infections
Staphylococcus aureus
Bacteremia
Undisclosed
Phage Candidate Pathogen &
Indication
Phase Partner
AP-PA02 P. aeruginosa
CF Lung Infection
Phase 1/2 (1H20)
AP-SA02 S. aureus
Bacteremia
Phase 1/2 (2H20)
Undisclosed Discovery Merck